767-P: Family Support for Medical Nutritional Therapy and Dietary Intake among Japanese Patients with Type 2 Diabetes

Although support from patients’ family members is essential in managing type 2 diabetes, evidence is sparse on family support for medical nutritional therapy (MNT) and habitual dietary intake. This study investigated the association between patients’ perception of family support for MNT and their dietary intake. Analyzed were 154 Japanese patients with type 2 diabetes (men, 45.5%) who completed the Food Frequency Questionnaire and Diabetes Family Behavior Checklist. Multivariate analysis of covariance was used adjusting for age, gender, BMI, duration for diabetes, HbA1c, and use of oral hypoglycemic agents and/or insulin. Participants’ mean age, duration of diabetes and HbA1c were 63.5 y, 12.7 y and 7.0%, respectively. After adjusting for confounders, positive family support, i.e., ‘Praise for following diet,’ was only significantly associated with higher fish intake (none 72.0 g/d, once a month 73.1 g/d, once a week 85.8 g/d, several times a week 97.6 g/d, and at least daily 92.1 g/d; trend p= 0.008). With greater frequency of eating at the same time as the family, salt intake was significantly higher (none 7.8 g/d, once a month 8.3 g/d, once a week 8.7 g/d, several times a week 9.3 g/d, and at least once daily 8.8 g/d; trend p= 0.037). Conversely, negative family support indicated by ‘Nags about following the diet’ was significantly associated with higher fish intake (none 70.3 g/d, once a month 84.4 g/d, once a week 84.3 g/d, several times a week 86.5 g/d, at least once daily 107.9 g/d; trend p= 0.012) and higher intake of vegetables was more frequent in those eating foods not part of the diabetic diet (none 242.1 g/d, once a month 192.1 g/d, once a week 270.4 g/d, several times a week 255.0 g/d, at least once daily 305.5 g/d; trend p= 0.027). These findings implied that patients’ perception of family support for MNT was not always associated with an ideal dietary intake to control diabetes. To facilitate diabetes treatment, sharing patient-family perceptions of MNT could be important. Disclosure C. Horikawa: None. Y. Takeda: None. M. Hatta: None. D. Ishii: None. S.Y. Morikawa: None. K. Fujihara: None. H. Maegawa: Research Support; Self; Antares Pharma, Boehringer Ingelheim Pharmaceuticals, Inc., Daiichi Sankyo Company, Limited, Mitsubishi Tanabe Pharma Corporation, Takeda Pharmaceutical Company Limited. Speaker's Bureau; Self; Astellas Pharma Inc., Boehringer Ingelheim Pharmaceuticals, Inc., Daiichi Sankyo Company, Limited, Merck Sharp & Dohme Corp., Mitsubishi Tanabe Pharma Corporation, Takeda Pharmaceutical Company Limited. H. Sone: Research Support; Self; Astellas Pharma Inc., Boehringer Ingelheim Pharmaceuticals, Inc., Daiichi Sankyo Company, Limited, Kowa Pharmaceutical Europe Co. Ltd., Kyowa Hakko Kirin Co., Ltd., Novo Nordisk Inc., Ono Pharmaceutical Co., Ltd., Taisho Pharmaceutical Co., Ltd., Takeda Pharmaceutical Company Limited, Teijin Pharma Limited. Funding Japan Association for Diabetes Education and Care